Clinical Consult


Management of Chemotherapy-Ineligible AML: Beyond HMA Monotherapy

August 3rd 2021

Eytan Stein, MD, discusses the management of chemotherapy-ineligible AML, as well as the effect of venetoclax in combination with HMA as a new therapy.

Therapeutic Decision-Making in the Adjuvant Setting in HR+ Breast Cancer

May 19th 2021

Best practices for the use of gene profiling assays to guide treatment decisions for patients with early-stage HR-positive breast cancer.

Relapsed/Refractory Multiple Myeloma: Targeted Therapy and BCMA

May 3rd 2021

Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.

Ovarian Cancer: Frontline Therapy

April 1st 2021

Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.

Impact of COVID-19 on the Management of Early-Stage Breast Cancer

February 9th 2021

Anthony Lucci, MD, provides insight on the management of early-stage breast cancer and evolving therapeutic approaches for patients due to the COVID-19 pandemic.

Using PARP Inhibitors in Frontline Maintenance Therapy of Ovarian Cancer

January 20th 2021

Thomas Herzog, MD, provides insight on key clinical trials and the use of PARP inhibition in frontline maintenance therapy for ovarian cancer.

Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma

October 27th 2020

BCMA targeting agents such as the antibody-drug conjugate belantamab mafodotin show promise for heavily pretreated patients with relapsed/refractory multiple myeloma

Multiple Myeloma: Targeting BCMA in the Heavily Pretreated Population

October 9th 2020

The rationale for using BCMA-targeted novel approaches such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies as treatment for patients with heavily pretreated relapsed/refractory multiple myeloma.

Assessing the Impact of TAILORx on Breast Cancer Management

June 16th 2020

ONCOLOGY® recently sat down with Jane L. Meisel, MD, of Emory University School of Medicine in Atlanta, Georgia, to discuss how these data from the TAILORx trial validate and inform the current and future care of patients with breast cancer.